Examples include BCR-ABL inhibitors for CML and ALL, such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib; Bruton tyrosine kinase inhibitors for CLL and lymphoma, including ibrutinib, acalabrutinib, and zanubrutinib; JAK inhibitors for myeloproliferative neoplasms, such as ruxolitinib and fedratinib; and FLT3 inhibitors for AML, such as midostaurin and gilteritinib. This evidence concerns the gene BTK and acute myeloid leukemia.